CN115210260A - 抗st2抗体及其应用 - Google Patents
抗st2抗体及其应用 Download PDFInfo
- Publication number
- CN115210260A CN115210260A CN202180010756.2A CN202180010756A CN115210260A CN 115210260 A CN115210260 A CN 115210260A CN 202180010756 A CN202180010756 A CN 202180010756A CN 115210260 A CN115210260 A CN 115210260A
- Authority
- CN
- China
- Prior art keywords
- seq
- variable region
- chain variable
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000852968 Homo sapiens Interleukin-1 receptor-like 1 Proteins 0.000 claims abstract description 73
- 239000012634 fragment Substances 0.000 claims abstract description 52
- 101000585365 Homo sapiens Sulfotransferase 2A1 Proteins 0.000 claims abstract description 50
- 108010067003 Interleukin-33 Proteins 0.000 claims abstract description 48
- 102000017761 Interleukin-33 Human genes 0.000 claims abstract description 48
- 201000010099 disease Diseases 0.000 claims abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 102000055002 human IL1RL1 Human genes 0.000 claims abstract description 23
- 230000014509 gene expression Effects 0.000 claims abstract description 11
- 230000037361 pathway Effects 0.000 claims abstract description 11
- 230000008482 dysregulation Effects 0.000 claims abstract description 8
- 239000013598 vector Substances 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 108020001507 fusion proteins Proteins 0.000 claims description 19
- 102000037865 fusion proteins Human genes 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 8
- 201000010105 allergic rhinitis Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 208000000592 Nasal Polyps Diseases 0.000 claims description 7
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 7
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010012735 Diarrhoea Diseases 0.000 claims description 6
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 claims description 5
- 241000288906 Primates Species 0.000 claims description 4
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 230000001588 bifunctional effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 230000000903 blocking effect Effects 0.000 abstract description 10
- 230000004071 biological effect Effects 0.000 abstract description 5
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 230000021995 interleukin-8 production Effects 0.000 abstract description 2
- 230000031146 intracellular signal transduction Effects 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 44
- 241001529936 Murinae Species 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 39
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 description 35
- 238000012216 screening Methods 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 18
- 150000001413 amino acids Chemical group 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 238000005406 washing Methods 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000012224 working solution Substances 0.000 description 9
- 239000013641 positive control Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 238000007865 diluting Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000010494 dissociation reaction Methods 0.000 description 7
- 230000005593 dissociations Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 102000000743 Interleukin-5 Human genes 0.000 description 5
- 108010002616 Interleukin-5 Proteins 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 101000998137 Homo sapiens Interleukin-33 Proteins 0.000 description 4
- 101100018717 Mus musculus Il1rl1 gene Proteins 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- -1 IFN- γ Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- 101100288142 Mus musculus Klkb1 gene Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000004091 panning Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 108091058560 IL8 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 description 2
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102100033500 Interleukin-33 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000009833 antibody interaction Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229950003468 dupilumab Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 102000045906 human IL33 Human genes 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000010599 interleukin-33 production Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 229950008998 tezepelumab Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102220512038 AP-4 complex subunit sigma-1_C259S_mutation Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 239000005984 Mepiquat Substances 0.000 description 1
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001715 anti-suppressor Effects 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102220348525 c.623G>C Human genes 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000055228 human IL5 Human genes 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- NNCAWEWCFVZOGF-UHFFFAOYSA-N mepiquat Chemical compound C[N+]1(C)CCCCC1 NNCAWEWCFVZOGF-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000002352 nuocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000003030 reporter gene method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
Abstract
提供了一种结合ST2的抗体或其片段，所述抗体或其片段能够特异性结合人ST2，抑制IL‑33与人ST2的结合，阻断IL‑33/ST2胞内信号通路途径，且抑制不同形式IL‑33对细胞IL5、IL6、IL8生成的促进作用，相比于已知抗ST2抗体，具有更高的生物学活性，可用于预防、治疗或改善与ST2表达或IL‑33/ST2途径失调相关的疾病。
Description
PCT国内申请，说明书已公开。
Claims (15)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010072085X | 2020-01-21 | ||
| CN202010072085.XA CN113214395A (zh) | 2020-01-21 | 2020-01-21 | 抗st2抗体及其应用 |
| PCT/CN2021/073009 WO2021147937A1 (zh) | 2020-01-21 | 2021-01-21 | 抗st2抗体及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115210260A true CN115210260A (zh) | 2022-10-18 |
Family
ID=76993069
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010072085.XA Pending CN113214395A (zh) | 2020-01-21 | 2020-01-21 | 抗st2抗体及其应用 |
| CN202180010756.2A Pending CN115210260A (zh) | 2020-01-21 | 2021-01-21 | 抗st2抗体及其应用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010072085.XA Pending CN113214395A (zh) | 2020-01-21 | 2020-01-21 | 抗st2抗体及其应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230220086A1 (zh) |
| EP (1) | EP4095160A4 (zh) |
| JP (1) | JP2023510972A (zh) |
| KR (1) | KR20220131970A (zh) |
| CN (2) | CN113214395A (zh) |
| AU (1) | AU2021210061A1 (zh) |
| CA (1) | CA3165698A1 (zh) |
| WO (1) | WO2021147937A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116284388A (zh) * | 2021-07-21 | 2023-06-23 | 迈威(上海)生物科技股份有限公司 | 抗肿瘤抑制素2的抗体以及包含其的液体组合物 |
| WO2023001258A1 (zh) * | 2021-07-21 | 2023-01-26 | 迈威(上海)生物科技股份有限公司 | 抗肿瘤抑制素2抗体的制药用途 |
| CN115703837B (zh) * | 2021-08-17 | 2023-10-03 | 东莞市朋志生物科技有限公司 | 一种抗生长刺激表达基因2蛋白的重组抗体 |
| CN117250356B (zh) * | 2023-05-23 | 2024-02-20 | 安徽千诚生物技术有限公司 | 一种定量检测可溶性st2蛋白的胶乳增强免疫比浊试剂盒及其制备方法 |
| CN117024595B (zh) * | 2023-10-08 | 2024-01-26 | 江西乐成欣生生物技术研究有限责任公司 | 抗人st2的单克隆抗体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001218871A1 (en) * | 2000-03-21 | 2001-10-03 | Takao Arai | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
| RU2597288C2 (ru) * | 2011-02-23 | 2016-09-10 | Ф. Хоффманн-Ля Рош Аг | Антитела против человеческого il33r и их применение |
| JO3623B1 (ar) * | 2012-05-18 | 2020-08-27 | Amgen Inc | البروتينات المرتبطة بمولد المستضاد st2 |
| US8603470B1 (en) * | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
| CN110045131B (zh) * | 2019-06-14 | 2019-09-03 | 迈威(上海)生物科技有限公司 | 用于测定人il-33/st2通路抑制剂的生物学活性的方法 |
| CN110357963B (zh) * | 2019-07-31 | 2020-09-18 | 北京智仁美博生物科技有限公司 | 抗人st2抗体及其用途 |
-
2020
- 2020-01-21 CN CN202010072085.XA patent/CN113214395A/zh active Pending
-
2021
- 2021-01-21 EP EP21745196.2A patent/EP4095160A4/en active Pending
- 2021-01-21 JP JP2022544124A patent/JP2023510972A/ja active Pending
- 2021-01-21 CA CA3165698A patent/CA3165698A1/en active Pending
- 2021-01-21 WO PCT/CN2021/073009 patent/WO2021147937A1/zh unknown
- 2021-01-21 CN CN202180010756.2A patent/CN115210260A/zh active Pending
- 2021-01-21 US US17/794,582 patent/US20230220086A1/en active Pending
- 2021-01-21 KR KR1020227029007A patent/KR20220131970A/ko unknown
- 2021-01-21 AU AU2021210061A patent/AU2021210061A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023510972A (ja) | 2023-03-15 |
| EP4095160A1 (en) | 2022-11-30 |
| WO2021147937A1 (zh) | 2021-07-29 |
| CA3165698A1 (en) | 2021-07-29 |
| US20230220086A1 (en) | 2023-07-13 |
| KR20220131970A (ko) | 2022-09-29 |
| EP4095160A4 (en) | 2024-05-22 |
| CN113214395A (zh) | 2021-08-06 |
| AU2021210061A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115210260A (zh) | 抗st2抗体及其应用 | |
| CN109937212B (zh) | B7-h3抗体、其抗原结合片段及其医药用途 | |
| JP5502752B2 (ja) | 抗ｍｉｆ抗体 | |
| US10689439B2 (en) | Optimized anti-TL1A antibodies | |
| TWI635097B (zh) | 新穎抗人類ｔｓｌｐ受體抗體 | |
| EP3430045B1 (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| HUE028458T2 (en) | High affinity anti-human IgE antibodies | |
| TW201722990A (zh) | 特異性結合tl1a之抗體 | |
| EP3430043B1 (en) | Anti-tnfalpha-antibodies and functional fragments thereof | |
| EP2552961B1 (en) | Humanized il-25 antibodies | |
| CN113501878B (zh) | 针对人tslp的多种抗体及其用途 | |
| CN107964045B (zh) | 一种人鼠嵌合抗CXCR2全分子IgG及其应用 | |
| CN114127110B (zh) | 抗cgrp抗体及其应用 | |
| JP2019516360A (ja) | ヒト化抗ｒａｇｅ抗体 | |
| JP2022513331A (ja) | ヒト化抗Ｎ短縮型アミロイドβモノクローナル抗体 | |
| CN114395042B (zh) | 抗il-33人源化抗体及其应用 | |
| WO2023141815A1 (zh) | 抗生长分化因子15的抗体分子及其应用 | |
| WO2023051656A1 (zh) | 双特异性抗体及其应用 | |
| WO2023001258A1 (zh) | 抗肿瘤抑制素2抗体的制药用途 | |
| CN117247451B (zh) | 一种针对人白介素6蛋白的单域抗体及其应用 | |
| JP7419544B2 (ja) | 抗ＩＬ－１β抗体 | |
| CN117586390A (zh) | 抗cgrp抗体及用途 | |
| TW202212359A (zh) | 結合人il-33的抗體、其製備方法和用途 | |
| CN114075284A (zh) | Cd47结合分子及其用途 | |
| CN117467014A (zh) | 结合人免疫球蛋白E（IgE）的羊驼源纳米抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |